arrow
N

Nikeshan Jeyakumar

stanford university school of medicine
H指数:8
被引数:349

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

在费城染色体阳性急性淋巴细胞白血病中使用Brexucabtagene Autoleucel治疗后,TKI维持疗法可改善疗效

2026-06-290
OA
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

CD22 CAR T细胞在B-ALL中的治疗效果:两种制造策略的故事

2025-10-020
PRE
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Brexucabtagene autoleucel在伴有CNS受累的复发/难治性急性淋巴细胞白血病患者中的疗效

2025-05-090
OAAI
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Brexucabtagene autoleucel治疗60岁及以上患者复发/难治性B细胞急性淋巴细胞白血病的有效性与安全性

BLOOD
IF23.1
2024-11-051
PRE
Barriers to the universal adoption of bilateral internal mammary artery grafting

普遍采用双侧乳内动脉移植术的障碍

2015-04-0115
OAAI